[18F]FS1P1 Radiotracer Synthesis for Neuroinflammation Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current F-18 radiotracers for S1P1 have issues with high non-specific binding, fast metabolism in vivo, and other concerns, limiting their clinical investigation for imaging and therapeutic applications.
Innovation Solution
Development of a multiple step F-18 labeling strategy to synthesize [18F]FS1P1, which shares the same structure with [11C]CS1P1, using a key ortho-nitrobenzaldehyde precursor and a tertiary amine additive TMEDA to achieve high radiochemical yield and purity, ensuring high brain uptake and metabolic stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current F-18 radiotracers for S1P1 are used, then imaging capability is provided, but high non-specific binding and fast metabolism in vivo occur
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of the radiotracer through multiple step F-18 labeling strategy. The synthesis uses a key ortho-nitrobenzaldehyde precursor with specific structural modifications to achieve high brain uptake and metabolic stability, directly addressing the non-specific binding and metabolism issues of previous tracers
Solution Approach 2:
The patent uses a tertiary amine additive TMEDA as an intermediary in the radiofluorination reaction. This intermediary facilitates the nucleophilic substitution reaction between F-18 and the ortho-nitrobenzaldehyde precursor, enabling high radiochemical yield and purity while maintaining the tracer's pharmacokinetic properties
2Manufacturing precision
If multiple step F-18 labeling strategy is used, then high radiochemical yield and purity are achieved, but synthesis complexity increases
Solution Approach 1:
The patent segments the synthesis process into distinct steps: (1) nucleophilic radiofluorination of ortho-nitrobenzaldehyde precursor to form [18F]FS1P1, (2) purification step, and (3) quality control. This segmentation allows each step to be optimized independently, achieving high radiochemical yield (30-50%) and purity (>95%) while managing the overall synthesis complexity
Solution Approach 2:
The patent employs preliminary action by preparing the ortho-nitrobenzaldehyde precursor in advance with specific functional groups positioned for optimal F-18 incorporation. The precursor is designed with pre-positioned substituents that facilitate the radiofluorination reaction and ensure high specific activity, reducing the need for additional purification steps
3Reliability
If [18F]FS1P1 is used for neuroinflammation imaging, then high brain uptake is achieved, but production and distribution constraints exist
Solution Approach 1:
The patent leverages the periodic properties of F-18 with its 110-minute half-life to optimize production and distribution timing. The synthesis protocol is designed to complete within this timeframe, allowing periodic production cycles at centralized facilities with distribution to multiple imaging centers, thereby achieving high brain uptake while managing logistical constraints
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
[18F]FS1P1 demonstrates high brain uptake and metabolic stability, with almost identical pharmacokinetics to [11C]CS1P1, making it a promising F-18 S1P1 radiotracer for neuroinflammation imaging and potential clinical use.
Implementation Method 1
PET imaging with [11C]CS1P1 radiotracer can quantitatively measure S1P1 expression changes
Implementation Method 2
uses radioisotope labeled ligands that bind to a target and release gamma rays that can be detected for localization and quantification
Implementation Method 3
A wide range of reaction conditions for the nucleophilic radiofluorination was explored starting with the key ortho-nitrobenzaldehyde precursor 10
Data Source
AI summary
The present disclosure generally relates to compounds and compositions for use in imaging agents, methods of use for monitoring and/or treating conditions or diseases related to sphingosine-1-phosphate (S1P) signaling, and processes for preparing these compositions and compounds.